Disc Medicine's anti-TMPRSS6 antibody DISC-3405 significantly reduces phlebotomy needs in polycythemia vera Phase II trial.
Tempus AI secures $9.5M federal funding to build autonomous heart failure AI agent. Discover how AI is transforming ...
Roche's Enspryng receives FDA priority review for MOGAD treatment. First potential therapy for rare autoimmune disease with no approved treatments.
FDA grants accelerated approval to Bayer's Hyrnuo (sevabertinib) as first-line therapy for HER2-mutated NSCLC. Learn about ...
McGill and Mount Sinai researchers discover PRMT7 suppresses CD8+ T cell expansion, offering new cancer immunotherapy targets ...
Insilico said the trial is intended to determine whether the efficacy and safety signals from the earlier Phase IIa study ...
BioNTech halts autogene cevumeran Phase II trial after safety board finds imbalance favoring control arm in colorectal cancer ...
Solstice Oncology secures $225M Series A to advance porustobart, a next-gen CTLA-4 antibody for neoadjuvant cancer treatment.
Independent research teams validate Apeximmune's PLA2G2D as key to overcoming anti-PD-1 resistance in cancer therapy. Read ...
Lee's Pharmaceutical licenses preclinical PARP1 inhibitor OC-3 from 1cBio for Greater China and Southeast Asia. Exclusive ...
TwoStep Therapeutics secures $62.5M Series A funding and FDA IND clearance for TS-104, a first-in-class peptide-drug ...
Alebund Pharmaceuticals receives FDA IND clearance for AP308, an engineered IgA protease for IgA nephropathy treatment. Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results